Monoferric (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monoferric, is an iron supplement presented as an intravenous (IV) solution for infusion use. It treats iron deficiency anemia by rapidly replenishing elemental iron in patients who require intravenous therapy.

GNH USA supplies Monoferric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products across multiple continents. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and dedicated technical support.

Monoferric is indicated for conditions associated with iron deficiency anemia, providing rapid iron repletion via the intravenous route. - Iron deficiency anemia: restores hemoglobin levels and replenishes iron stores in patients with confirmed iron deficiency anemia. - Iron deficiency anemia in chronic kidney disease: improves anemia management in CKD patients who are non‑responsive or intolerant to oral iron. - Iron deficiency anemia in inflammatory bowel disease: corrects anemia when gastrointestinal inflammation limits oral iron absorption. - Peri‑operative iron deficiency anemia: prepares patients for surgery by quickly correcting anemia and reducing transfusion risk.

Intravenous iron therapy can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring during or after infusion. - Headache: transient headache reported by some patients. - Injection site pain: discomfort or burning sensation at the infusion site. - Flushing: brief redness or warmth sensation.

Serious or Rare Side Effects: - Hypersensitivity reactions: anaphylaxis or severe allergic response requiring immediate medical attention. - Hypotension: sudden drop in blood pressure during infusion. - Iron overload: excessive iron accumulation leading to organ dysfunction if dosing is not properly monitored.

When using Monoferric, clinicians should observe specific precautions to minimize risks and ensure product integrity. - Patient assessment: confirm iron deficiency anemia and evaluate for contraindications before infusion. - Monitoring: observe vital signs and signs of hypersensitivity during and after administration. - Concomitant medications: avoid concurrent use of other parenteral iron products. - Renal function: assess kidney function as impaired clearance may affect iron handling. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Ferric derisomaltose may interact with certain medicines, altering its safety or efficacy.

Major Interactions (Avoid): - Erythropoiesis‑stimulating agents: concurrent use can increase risk of hypertension and thrombotic events. - High‑dose vitamin C: may enhance iron absorption and increase risk of oxidative stress.

Moderate Interactions (Monitor Closely): - Oral iron supplements: may cause additive iron load; monitor total iron intake. - Antacids containing aluminum or magnesium: can reduce iron availability if administered close to infusion time.